



ASX Market Announcement

Receipt of R&D Tax Incentive Refund for geneType Multi Test

Melbourne, Australia, 17 February 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, "Company", "GTG"), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to advise that the Company has received \$1.96m from the federal government's Research and Development (R&D) Tax Incentive program for the 2022 financial year.

The amount received represents 43.5% of the Company's eligible R&D expenditure for the 2022 financial year. A significant portion of the expenditure incurred during the 2022 financial year related to the research and development of the geneType multi-test.

-END-

Authorised for release by the board of directors of Genetic Technologies Limited.

Enquiries

Investor Relations

Adrian Mulcahy

Automic Markets

M: +61 438 630 411

E: adrian.mulcahy@automicgroup.com.au

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com